Mandate

Vinge advises CELLINK in connection with listing on Nasdaq First North

October 07, 2016

Vinge has advised CELLINK AB (publ) in connection with its listing on Nasdaq First North.

The information memorandum was published on 7 October 2016 and the estimated first day of trading is 3 November 2016. The subscription price in the offer is SEK 26 per share, which corresponds to a pre-money value for CELLINK of approximately MSEK 156. No shares or other securities are being sold by existing shareholders in connection with the offer.

CELLINK develops and sells bioink and bioprinters. Bioink can be combined with conductive cells in order to print functional living tissue and, if future research is successful, complete human organs. CELLINK was founded in 2016 and has won several awards, both scientific and business related, for successful entrepreneurship.

 Vinge’s team consisted of responsible partner Anders Strid together with Frida Bäckegren (capital markets), Jonas Lindblad (employment), Joel Zetterström and Natalie Bäck (IT), Karin Wisenius (competition), Victor Ericsson (tax) and corporate assistant Camilla Andersson.    

Related

Vinge advises Isofol Medical AB (publ) in connection with its rights issue of units

Through the rights issue of units, consisting of shares and warrants, and the exercised over-allotment issue, Isofol will receive approximately SEK 84 million and may receive an additional maximum of approximately SEK 110 million upon exercise of all warrants at the highest subscription price.
August 01, 2025

Vinge advises Oncorena in connection with share issue

Vinge advises Oncorena Holding AB in connection with a share issue of approximately SEK 133 million.
July 30, 2025

Vinge advises Karl Hedin and minority owners on the sale of AB Karl Hedin Sågverk to Vida

Vinge has advised Karl Hedin and minority shareholders in connection with the sale of AB Karl Hedin Sågverk to Vida Aktiebolag (“Vida”).
July 24, 2025